Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group

Affiliations

• ¹ Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
• ² Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
• ³ Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany.
• ⁴ Department of Oncology and Hematology, Klinikum Oldenburg, Oldenburg, Germany.
• ⁵ Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
• ⁶ Department of Internal Medicine III, University Hospital of Bonn, Bonn, Germany.
• ⁷ Department of Internal Medicine II, University Hospital Schleswig-Holstein Kiel, Kiel, Germany.
• ⁸ Department of Hematology and Oncology, University Hospital of Göttingen, Göttingen, Germany.
• ⁹ Department of Internal Medicine III, University Hospital of Munich, Munich, Germany.
• ¹⁰ Department of Internal Medicine III, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany.
• ¹¹ Hubertus Wald University Cancer Center, Department of Oncology and Hematology, University Medical Center Eppendorf, Hamburg, Germany.
• ¹² Internal Medicine V, University Hospital of Innsbruck, Innsbruck, Austria.
• ¹³ Third Department of Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
• ¹⁴ Department of Internal Medicine I, University Hospital of Saarland, Homburg, Germany.
• ¹⁵ Department of Medicine, Division of Hematology and Oncology, University Hospital of Freiburg, Freiburg, Germany.
• ¹⁶ Department of Hematology and Oncology, Kliniken Essen Süd, Essen, Germany.
• ¹⁷ Department of Hematology and Oncology, Eberhard Karls-University, Tübingen, Germany.
• ¹⁸ Department of Internal Medicine III, Städtisches Klinikum Braunschweig, Braunschweig, Germany.